Confirmation of genetic variants associated with lethal prostate cancer in a cohort of men from hereditary prostate cancer families

International Journal of Cancer

Volumn 136, Issue 9, 2015, Pages 2166-2171

  Karyadi, Danielle M ^a   Zhao, Shanshan ^b   He, Qianchuan ^b   McIntosh, Laura ^b   Wright, Jonathan L ^b,c   Ostrander, Elaine A ^a   Feng, Ziding ^d   Stanford, Janet L ^b,e  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

AKT1; Hereditary prostate cancer; Mortality; RNASEL; SNPs; XRCC1

Indexed keywords

AKT1; BIOLOGICAL MARKER; PROTEIN KINASE B; RIBONUCLEASE L; UNCLASSIFIED DRUG; XRCC1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER FAMILY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DEATH CERTIFICATE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FAMILIAL CANCER; FAMILY HISTORY; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; GERM LINE; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; LETHALITY; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROGNOSIS; PROSTATE TUMOR; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84923198041     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29241     Document Type: Article

References (28)

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute 2014. Available at: Http://seer.cancer.gov/csr/19752011/.
2. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013. Available at: Http://globocan.iarc.fr/.
3. Epstein MM, Edgren G, Rider JR, et al. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst 2012;104: 1335-42.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62: 10-29.
5. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J ClinOncol 2010;28: 1117-23.
6. Boorjian SA, Eastham JA, Graefen M, et al. A critical analysis of the long-Term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 2012;61: 664-75.
7. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177: 2106-31.
8. Lin DW, FitzGerald LM, Fu R, et al. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev 2011;20: 1928-36.
9. Penney KL, Shui IM, Feng Z, et al. Replication of a genetic variant for prostate cancer-specific mortality. 2014 (submitted).
10. Stanford JL, FitzGerald LM, McDonnell SK, et al. Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. Hum Mol Genet 2009;18: 1839-48.
11. Fritz A, Ries L. SEER Extent of Disease, 1988, Codes and Coding Instructions, 3rd edn., 1998. Available at: Http://www.seer.cancer.gov/manuals/EOD10Dig.3rd.pdf.
12. Sambrook J, Fritsch EF, Maniatis T. Isolation of high-molecular weight DNA from mammalian cells. In: Nolan C, ed. Molecular cloning: A laboratory manual, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 1989. pp 9.16-9.9.
13. Pankratz VS, de Andrade M, Therneau TT. Random-effects Cox proportional hazards model: General variance components methods for timeto-event data. Genetic Epidemiol 2005;28: 97-109.
14. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: The R Foundation for Statistical Computing, 2014. Available at: Http://www.Rproject. org/.
15. Brennan-Laun SE, Ezelle HJ, Li X-L, et al. RNase-L control of cellular mRNAs: Roles in biologic functions and mechanisms of substrate targeting. J Inteferon Cytokine Res 2014;34: 275-88.
16. Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002;30: 181-4.
17. Bettoun DJ, Scafonas A, Rutledge SJ, et al. Interaction between the androgen receptor and Rnase L mediates cross-Talk between the interferon and androgen signaling pathways. J Biol Chem 2005; 280: 38898-901.
18. Schoenfeld JD, Margalit DN, Kasperzyk JL, et al. A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for loclized prostate cancer. Clin Cancer Res 2013;19: 1612-19.
19. Meyer MS, Penney KL, Stark JR, et al. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis 2010; 31: 1597-603.
20. Alvarez-Cubero MJ, Entrala C, Fernandez-Rosado F, et al. Predictive value in the analysis of RNASEL genotypes in relation to prostate cancer. Prostate Cancer Prostatic Dis 2012;15: 144-9.
21. San Francisco IF, Rojas PA, Torres-Estay V, et al. Association of RNASEL and 8q24 variants with the presence and aggressiveness of hereditary and sporadic prostate cancer in a Hispanic population. J Cell Mol Med 2014;18: 125-33.
22. Ginsberg G, Angle K, Guyton K, et al. Polymorphism in the DNA repair enzyme XRCC1: Utility of current database and implications for human health risk assessment. Mutat Res 2011;727: 1-15.
23. Iyama T, Wilson DM, III. DNA repair mechanisms in dividing and non-dividing cells. DNA Repair 2013;12: 620-36.
24. Wei B, Zhou Y, Xu Z, et al. XRCC1 Arg399Gln and Arg194Trp polymorphisms in prostate cancer risk: A meta-Analysis. Prostate Cancer Prostatic Dis 2011;14: 225-31.
25. Langsenlehner T, Renner W, Gerger A, et al. Association between single nucleotide polymorphisms in the gene for XRCC1 and radiationinduced late toxicity in prostate cancer patients. Radiother Oncol 2011;98: 387-93.
26. Cheung M, Testa JR. Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets 2013;13: 234-44.
27. Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal. 2011;23: 1515-27.
28. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005;24: 7443-54.